Quarterly report pursuant to Section 13 or 15(d)

CONDENSED BALANCE SHEETS

v3.19.2
CONDENSED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2019
Dec. 31, 2018
Current assets:    
Cash and cash equivalents $ 2,292 $ 9,295
Restricted cash 0 361
Receivables 1,140 1,737
Inventory 1,317 1,262
Contract assets 0 99
Prepaid expenses and other current assets 744 547
Total current assets 5,493 13,301
Property and equipment, net 754 794
Operating lease right-of-use asset 514 0
Total assets 6,761 14,095
Current liabilities:    
Accounts payable 1,025 1,526
Accrued clinical trials expenses 504 620
Accrued sales allowances 830 0
Other accrued liabilities 397 466
Deferred revenue 0 313
Operating lease liability, current 253 0
Current portion of long-term debt 1,333 527
Total current liabilities 4,342 3,452
Operating lease liability, non-current 292 0
Long-term debt 2,698 3,787
Derivative liability 0 25
Total liabilities 7,332 7,264
Stockholders' (deficit) equity:    
Common stock, $0.001 par value per share: 125,000 shares authorized; 14,262 and 13,010 shares issued and outstanding at June 30, 2019 and December 31, 2018 14 13
Additional paid-in capital 341,708 339,397
Accumulated deficit (342,293) (332,579)
Total stockholders' (deficit) equity (571) 6,831
Total liabilities and stockholders' (deficit) equity $ 6,761 $ 14,095